Hydrogenics Corp. is a leading developer and manufacturer of hydrogen generation and fuel cell products. The company’s products are used in various applications, including electric cars, freestanding power plants, fueling stations, industrial processes and in wind and solar power systems.
The company today announced that it has been selected by the city of Herten, Germany (a center for renewable energy projects) to provide a wind-hydrogen energy storage solution. Wind energy is renewable source of power for communities looking to offset the demand traditionally served by power plants fueled by fossil fuels such as coal, oil and natural gas. It is also ideal for Germany, which is scheduled to phase out all nuclear power by 2020.
To meet the project requirements, Hydrogenics will provide one HySTAT 30 hydrogen generation unit and a HyPM 50 kilowatt fuel cell power system to Herten in 2012. This combination will demonstrate the distinct advantage of hydrogen energy storage with its ability to be highly scalable and capable of storing significant amounts of energy for long periods of time with negligible loss and zero carbon emissions.
From storage, the energy will be redeployed through fuel cells as electricity to the grid. Or as an alternative, it will be used to fuel zero emission vehicles and other devices such as industrial equipment.
For further insight into Hydrogenics and its technology, please visit the company’s website at www.hydrogenics.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wednesday, October 12, 2011
Tuesday, October 11, 2011
SMTC Corp. (SMTX) Announces Manufacturing Partnership with Prim’Tools
SMTC Corp. just announced the execution of a manufacturing partnership with Prim’Tools, one of the world’s most prominent manufacturers and distributors of laser level surveying equipment and measurement devices. Prim’Tools is part of Hexagon Group, a world leader in design, measurement, and visualization technologies and solutions.
SMTC’s Dongguan, China based manufacturing facility will provide Prim’Tools with a complete turn-key manufacturing solution for its next generation of laser precision measurement equipment. SMTC has assembled a dedicated core team for new product introduction (NPI) and performed design for manufacturing (DFM) analyses as part of its engineering solution based services. The company has also agreed to provide complex electronic manufacturing services, including Printed Circuit Board Assembly (PCBA) production, board level assembly and testing.
By leveraging SMTC’s expertise in Supply Chain Management (SCM) services, Prim’Tools gains a well-established network of material sourcing and purchasing power to help drive costs and reduce delivery times. Eric Lee, General Manager of Prim’Tools, stated, “We are confident that SMTC will be committed to providing Prim’Tools with excellent turn-key solutions and we very much look forward to building on this partnership as we move forward.”
“We’re delighted to welcome Prim’Tools as our newest customer,” commented Andy Li, Vice President and General Manager of SMTC China. “Our customers rely on our dedicated people and manufacturing capabilities as they deliver mission critical solutions to their end customers. We look forward to partnering with Prim’Tools to deliver superior service and operational excellence.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
SMTC’s Dongguan, China based manufacturing facility will provide Prim’Tools with a complete turn-key manufacturing solution for its next generation of laser precision measurement equipment. SMTC has assembled a dedicated core team for new product introduction (NPI) and performed design for manufacturing (DFM) analyses as part of its engineering solution based services. The company has also agreed to provide complex electronic manufacturing services, including Printed Circuit Board Assembly (PCBA) production, board level assembly and testing.
By leveraging SMTC’s expertise in Supply Chain Management (SCM) services, Prim’Tools gains a well-established network of material sourcing and purchasing power to help drive costs and reduce delivery times. Eric Lee, General Manager of Prim’Tools, stated, “We are confident that SMTC will be committed to providing Prim’Tools with excellent turn-key solutions and we very much look forward to building on this partnership as we move forward.”
“We’re delighted to welcome Prim’Tools as our newest customer,” commented Andy Li, Vice President and General Manager of SMTC China. “Our customers rely on our dedicated people and manufacturing capabilities as they deliver mission critical solutions to their end customers. We look forward to partnering with Prim’Tools to deliver superior service and operational excellence.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Rocky Mountain Chocolate Factory (RMCF) Posts Sweet Q2, FY2012 Results
Rocky Mountain Chocolate Factory Inc., an international franchiser of gourmet chocolate and self-serve frozen yogurt stores and manufacturer of premium chocolates and other confectionery products, today reported its operating results for the second quarter and first half of fiscal year 2012.
For the second quarter of fiscal 2012, the company reported total revenues of $7.6 million, an increase of 14.3 percent compared to revenues of approximately $6.6 million in the second quarter of fiscal 2011.
Retail sales increased 58.7 percent to $1.4 million for the second quarter of 2012 compared to $923,000 in the comparable quarter of 2011. Same-store sales at company-owned stores increased 4.1 percent in the second quarter of 2012 compared with the second quarter of 2011.
Rocky Mountain Chocolate posted a 3.4 percent decline in net income for the second quarter of 2012 at $912,000, or $0.15 basic earnings per share, compared to $944,000, or $0.14 basic earnings per share, reported in the second quarter of FY2011. Diluted earnings per share decreased 6.7 percent to $0.14 in the second quarter of 2012 compared to $0.15 in the second quarter of 2011.
Bryan Merryman, chief operating officer of Rocky Mountain Chocolate, said the company opened four company-owned ALY stores in the first six months and has signed leases for five additional stores that will begin opening in November of this year. The company also opened two franchised ALY during the second quarter, with a third in September.
Merryman said the company anticipates maintained growth in the recently opened stores.
“Although none of the ALY stores has been open long enough for us to evaluate their full-year operating metrics, we have been pleased to date with the sales generated by the company-owned and franchised ALY stores,” Merryman stated in the press release. “We believe our entry into the frozen self-serve yogurt market has the potential to significantly enhance shareholder value in coming years, as this new initiative complements our chocolate store business, leverages our three decades of experience in franchising and provides diversification of our revenue base.”
The company also posted results for the first six months of fiscal 2012, reporting that total revenues increased 13.8 percent to approximately $16.2 million, compared with revenues of approximately $14.2 million in the first half of 2011. Retail sales increased 63.7 percent to $2.8 million in the first half of 2012 compared to $1.7 million in the first half of 2011. Same-store retail sales at company-owned stores increased 4.1 percent in the first half of 2012 when compared with the first half of 2011. Net income for the first half of fiscal 2012 declined 2.3 percent to $1.8 million, or $0.30 basic earnings per share, compared to $1.8 million, or $0.31 basic earnings per share, in the first half of 2011. Diluted earnings per share of $0.29 in the first half of 2012 were 3.3 percent lower than the $0.30 per share reported in the first half of 2011.
For more information visit www.rmcf.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
For the second quarter of fiscal 2012, the company reported total revenues of $7.6 million, an increase of 14.3 percent compared to revenues of approximately $6.6 million in the second quarter of fiscal 2011.
Retail sales increased 58.7 percent to $1.4 million for the second quarter of 2012 compared to $923,000 in the comparable quarter of 2011. Same-store sales at company-owned stores increased 4.1 percent in the second quarter of 2012 compared with the second quarter of 2011.
Rocky Mountain Chocolate posted a 3.4 percent decline in net income for the second quarter of 2012 at $912,000, or $0.15 basic earnings per share, compared to $944,000, or $0.14 basic earnings per share, reported in the second quarter of FY2011. Diluted earnings per share decreased 6.7 percent to $0.14 in the second quarter of 2012 compared to $0.15 in the second quarter of 2011.
Bryan Merryman, chief operating officer of Rocky Mountain Chocolate, said the company opened four company-owned ALY stores in the first six months and has signed leases for five additional stores that will begin opening in November of this year. The company also opened two franchised ALY during the second quarter, with a third in September.
Merryman said the company anticipates maintained growth in the recently opened stores.
“Although none of the ALY stores has been open long enough for us to evaluate their full-year operating metrics, we have been pleased to date with the sales generated by the company-owned and franchised ALY stores,” Merryman stated in the press release. “We believe our entry into the frozen self-serve yogurt market has the potential to significantly enhance shareholder value in coming years, as this new initiative complements our chocolate store business, leverages our three decades of experience in franchising and provides diversification of our revenue base.”
The company also posted results for the first six months of fiscal 2012, reporting that total revenues increased 13.8 percent to approximately $16.2 million, compared with revenues of approximately $14.2 million in the first half of 2011. Retail sales increased 63.7 percent to $2.8 million in the first half of 2012 compared to $1.7 million in the first half of 2011. Same-store retail sales at company-owned stores increased 4.1 percent in the first half of 2012 when compared with the first half of 2011. Net income for the first half of fiscal 2012 declined 2.3 percent to $1.8 million, or $0.30 basic earnings per share, compared to $1.8 million, or $0.31 basic earnings per share, in the first half of 2011. Diluted earnings per share of $0.29 in the first half of 2012 were 3.3 percent lower than the $0.30 per share reported in the first half of 2011.
For more information visit www.rmcf.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Monday, October 10, 2011
Rimage (RIMG) and Qumu Join Forces to Boost Presence in Video Communications Market
Rimage Corp., a leading provider of on-demand CD/DVD/Blu-ray Disc™ publishing systems, today announced that it has signed a definitive agreement to acquire enterprise video communications provider Qumu Inc.
Rimage will pay $52 million for the acquisition, which will provide Rimage with a solid presence in the video communications market as the company has established relationships with 100 Global 1000 customers. Notably, Qumu revenues have increased more than 45 percent per year over the past three years.
“Qumu is a cornerstone acquisition for Rimage and immediately positions us as a leader in the growing market for video communications and social enterprise applications for business,” Sherman Black, president and CEO of Rimage stated in the press release. “The Qumu acquisition accelerates Rimage’s strategy to distribute live, on-demand, downloaded and optical media content for a broad range of applications, on any mobile or desktop device. This acquisition significantly expands our market to new enterprise customers and offers opportunities for cross-selling to the installed base of customers of both Rimage and Qumu.”
Qumu sells its products through a direct sales force to banking, technology, telecom, universities and government agencies, among others. Revenues for 2010 totaled $10.3 million, and the company said it is on track to achieve approximately $15 million in 2011. Qumu is expected to generate approximately $21 million in revenue in 2012.
“As a result of the Qumu acquisition, Rimage is positioned to generate double digit top line growth in 2012. Overall, we anticipate cash from operations in 2012 to match the level of cash generated in 2011. Given our expected cash position post-acquisition and our confidence in generating overall growth in 2012, we believe a 70 percent dividend increase is warranted,” Black stated.
Qumu will be integrated into Rimage, enabling Rimage to offer its customers a suite of solutions for all content distribution applications across multiple platforms, including the desktop, smart phones and tablets.
“We are extremely excited to be joining forces with Rimage to more quickly extend Qumu’s unique video communications solution to a much larger market,” Ray Hood, president and CEO of Rimage stated. “We believe the combination of the two companies offers significant opportunities for growth in 2012 and beyond. Our optimism is demonstrated by the desire of our investors to take a portion of the purchase price in Rimage stock.”
Per the acquisition agreement, Hood will remain the leader of the Qumu team and will become senior vice president of Rimage.
For more information visit www.rimagecorp.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Rimage will pay $52 million for the acquisition, which will provide Rimage with a solid presence in the video communications market as the company has established relationships with 100 Global 1000 customers. Notably, Qumu revenues have increased more than 45 percent per year over the past three years.
“Qumu is a cornerstone acquisition for Rimage and immediately positions us as a leader in the growing market for video communications and social enterprise applications for business,” Sherman Black, president and CEO of Rimage stated in the press release. “The Qumu acquisition accelerates Rimage’s strategy to distribute live, on-demand, downloaded and optical media content for a broad range of applications, on any mobile or desktop device. This acquisition significantly expands our market to new enterprise customers and offers opportunities for cross-selling to the installed base of customers of both Rimage and Qumu.”
Qumu sells its products through a direct sales force to banking, technology, telecom, universities and government agencies, among others. Revenues for 2010 totaled $10.3 million, and the company said it is on track to achieve approximately $15 million in 2011. Qumu is expected to generate approximately $21 million in revenue in 2012.
“As a result of the Qumu acquisition, Rimage is positioned to generate double digit top line growth in 2012. Overall, we anticipate cash from operations in 2012 to match the level of cash generated in 2011. Given our expected cash position post-acquisition and our confidence in generating overall growth in 2012, we believe a 70 percent dividend increase is warranted,” Black stated.
Qumu will be integrated into Rimage, enabling Rimage to offer its customers a suite of solutions for all content distribution applications across multiple platforms, including the desktop, smart phones and tablets.
“We are extremely excited to be joining forces with Rimage to more quickly extend Qumu’s unique video communications solution to a much larger market,” Ray Hood, president and CEO of Rimage stated. “We believe the combination of the two companies offers significant opportunities for growth in 2012 and beyond. Our optimism is demonstrated by the desire of our investors to take a portion of the purchase price in Rimage stock.”
Per the acquisition agreement, Hood will remain the leader of the Qumu team and will become senior vice president of Rimage.
For more information visit www.rimagecorp.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Wave Systems Corp. (WAVX) Announces Global Expansion with Addition of IT Security Veteran Joseph Souren
Located in London, Wave has quickly earned a stellar reputation on Wall Street for reducing complexity, cost and uncertainty of data protection. Today, Wave announced the company plans to expand into Europe, the Middle East and Africa to capitalize on the growing demand for trusted computing security solutions that help organizations thwart the rise in cyber threat and comply with EU data protection regulations.
To lead this new wave of expansion, Wave has named security veteran Joseph Souren, MBS, Vice President and General Manager, EMEA to execute a sales strategy and build out the company’s channel program. Souren has led an illustrious career where he most recently served as VP of CA Technologies’ Internet Security Business Unit.
With an already strong customer-base in Europe through an array of customer relationships, EMEA will bring greater notoriety and acclaim to the young company. In reference to such expansion, Wave’s Executive Vice President of Marketing and Sales stated, “EMEA is a critical market for Wave and we’re committing greater resources and personnel to expand our customer base there. With yesterday’s security failing organizations at an alarming rate, it’s increasingly clear that organizations need a better approach — one rooted in hardware — to secure their networks and protect their data. Wave brings the knowledge and experience to provide businesses with the framework to establish a known computing environment.”
Commenting on why he joined the team at Wave, Mr. Souren stated, “I joined Wave for one reason — it has unrivaled expertise, knowledge and technology to uniquely address the crisis in global network security. Wave offers a framework for establishing greater security, ensuring that data thieves cannot steal the ‘crown jewels’ of the organization — its intellectual property. We are committed to retaining and expanding the current channel program, and adding local support resources. The VAR channel is especially important in EMEA.”
Currently, Wave Systems is trading in the $2.62 range. To learn more about the company as a whole, visit their corporate website at: www.wave.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
To lead this new wave of expansion, Wave has named security veteran Joseph Souren, MBS, Vice President and General Manager, EMEA to execute a sales strategy and build out the company’s channel program. Souren has led an illustrious career where he most recently served as VP of CA Technologies’ Internet Security Business Unit.
With an already strong customer-base in Europe through an array of customer relationships, EMEA will bring greater notoriety and acclaim to the young company. In reference to such expansion, Wave’s Executive Vice President of Marketing and Sales stated, “EMEA is a critical market for Wave and we’re committing greater resources and personnel to expand our customer base there. With yesterday’s security failing organizations at an alarming rate, it’s increasingly clear that organizations need a better approach — one rooted in hardware — to secure their networks and protect their data. Wave brings the knowledge and experience to provide businesses with the framework to establish a known computing environment.”
Commenting on why he joined the team at Wave, Mr. Souren stated, “I joined Wave for one reason — it has unrivaled expertise, knowledge and technology to uniquely address the crisis in global network security. Wave offers a framework for establishing greater security, ensuring that data thieves cannot steal the ‘crown jewels’ of the organization — its intellectual property. We are committed to retaining and expanding the current channel program, and adding local support resources. The VAR channel is especially important in EMEA.”
Currently, Wave Systems is trading in the $2.62 range. To learn more about the company as a whole, visit their corporate website at: www.wave.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Friday, October 7, 2011
VistaGen Therapeutics, Inc. (VSTA) Potential Rewards Far Exceed Its Current Market Valuation
Over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceutical industry. It’s not unusual for a company to invest more than a billion dollars, and over a decade of skilled resources, to get a new drug candidate to market. The fact is that even the most promising candidates can be shelved late in the game, long after the money and time have been spent, due to toxicity issues that were not discovered earlier. It’s a huge loss to the developing company, but a greater loss to the people whose lives could have been improved or even saved.
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive and clinically-relevant in vitro toxicology bioassay systems, many of these hibernating drug candidates could be revived and developed as variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (“drug rescue variants”) of promising drug candidates that have been discontinued during preclinical development (“put on the shelf”) due to heart or liver safety concerns.
VistaGen’s versatile stem cell technology platform, Human Clinical Trials in a Test Tube, has been developed to provide clinically relevant indications, or predictions, of potential toxicity of new drug candidates before they are ever tested on humans. VistaGen’s human pluripotent stem cell-based bioassays more closely approximate human biology than conventional animal studies and nonclinical in vitro techniques and technologies currently used in drug development.
Using mature human heart cells produced from pluripotent stem cells, VistaGen leveraged its Human Clinical Trials in a Test Tube platform to develop CardioSafe 3D, a three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. The Company now plans to leverage CardioSafe 3D to build a pipeline of new, safer, variants of once promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VistaGen is also developing LiverSafe 3D, a predictive liver toxicity and drug metabolism bioassay system, and is preparing to initiate pilot preclinical development of cell therapy programs focused on autologous bone marrow transplantation and heart, liver and cartilage repair. Each of these development programs is based on the proprietary human pluripotent stem cell differentiation and cell production capabilities of the Company’s Human Clinical Trials in a Test Tube platform.
Since inception, VistaGen has obtained and employed more than $41 million from various strategic collaborations, investments and grant awards. Although investing in a small-cap company involves more risk, investors would be wise not to overlook the potential rewards as they far exceed the current market valuation of the Company (approximately $41 million market cap as of October 7, 2011). Revenues generated by just one drug successfully rescued and brought to market can total hundreds of millions, if not billions, of dollars within a couple years. Even more importantly, rescuing a drug candidate means the chance for rescued lives. Better cells make better medicine.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
This is not an isolated problem. It is estimated that approximately a third of all potential new drug candidates fail to meet safety requirements in preclinical or clinical trials. The result is a massive inventory of promising drugs that are currently discontinued due to safety concerns. However, with more predictive and clinically-relevant in vitro toxicology bioassay systems, many of these hibernating drug candidates could be revived and developed as variants which are as effective as the original, but without the safety concerns.
VistaGen Therapeutics, Inc. is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants (“drug rescue variants”) of promising drug candidates that have been discontinued during preclinical development (“put on the shelf”) due to heart or liver safety concerns.
VistaGen’s versatile stem cell technology platform, Human Clinical Trials in a Test Tube, has been developed to provide clinically relevant indications, or predictions, of potential toxicity of new drug candidates before they are ever tested on humans. VistaGen’s human pluripotent stem cell-based bioassays more closely approximate human biology than conventional animal studies and nonclinical in vitro techniques and technologies currently used in drug development.
Using mature human heart cells produced from pluripotent stem cells, VistaGen leveraged its Human Clinical Trials in a Test Tube platform to develop CardioSafe 3D, a three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. The Company now plans to leverage CardioSafe 3D to build a pipeline of new, safer, variants of once promising drug candidates that have been “put on the shelf” by pharmaceutical companies because of toxicity concerns, despite positive efficacy data signaling their potential therapeutic and commercial benefits.
VistaGen is also developing LiverSafe 3D, a predictive liver toxicity and drug metabolism bioassay system, and is preparing to initiate pilot preclinical development of cell therapy programs focused on autologous bone marrow transplantation and heart, liver and cartilage repair. Each of these development programs is based on the proprietary human pluripotent stem cell differentiation and cell production capabilities of the Company’s Human Clinical Trials in a Test Tube platform.
Since inception, VistaGen has obtained and employed more than $41 million from various strategic collaborations, investments and grant awards. Although investing in a small-cap company involves more risk, investors would be wise not to overlook the potential rewards as they far exceed the current market valuation of the Company (approximately $41 million market cap as of October 7, 2011). Revenues generated by just one drug successfully rescued and brought to market can total hundreds of millions, if not billions, of dollars within a couple years. Even more importantly, rescuing a drug candidate means the chance for rescued lives. Better cells make better medicine.
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Cerner Corp. (CERN) Acquires Clairvia
Today, Cerner Corp. announced it has reached an agreement to acquire Clairvia, a health care workforce management solutions provider. Clairvia’s software applications and predictive models enable health care organizations to align staff and resources with patient needs in real-time, allowing caregivers to focus solely on patient care. The solutions advance patient care quality, safety and throughput, staff productivity and satisfaction, reimbursements and cost control.
The acquisition is anticipated to close in October 2011 and is not expected to have a material impact on Cerner’s 2011 financial results. Clairvia’s President and CEO, Beth Pickard, will join Cerner effective upon closure of the transaction.
Over 400 organizations across the globe currently use Clairvia’s solutions, ranging in size from large health care systems to specialty physician practices. These clients utilize a variety of electronic health record (EHR) systems, as Clairvia’s solutions are EHR-system agnostic and integrate with numerous platforms, including Cerner Millennium®. Clairvia’s Care Value Management suite will be integrated into Cerner’s broader cloud-based and interoperability platforms, Cerner Healthe Intent™ and CareAware®. This will allow Cerner to offer a comprehensive suite of resource management solutions.
“Health care worldwide is experiencing a resourcing deficit that is forecasted to grow dramatically in the next several years,” said Jeff Townsend, Cerner executive vice president and chief of staff. “The fundamental supply of staff and other assets simply cannot meet rising patient demand. Clairvia’s predictive models driven by EHR data not only cut costs by aligning the right resource at the right time but, more importantly, optimize patient outcomes. With this acquisition, we are solidifying our commitment to the workforce management marketplace and interoperable cloud-based solutions that focus on providing positive clinical, operational and financial returns for our clients.”
“EHRs document patient needs and expected courses of care while resource management systems store nurse competency, skills and availability data,” said Pickard, Clairvia president and chief executive officer. “We integrate those two databases in real time, at the point of care. Cerner’s resources and dedication to improving health opens the door for us to create additional solutions that enable health care organizations to accurately forecast demand and to proactively align staffing resources to meet that demand.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
The acquisition is anticipated to close in October 2011 and is not expected to have a material impact on Cerner’s 2011 financial results. Clairvia’s President and CEO, Beth Pickard, will join Cerner effective upon closure of the transaction.
Over 400 organizations across the globe currently use Clairvia’s solutions, ranging in size from large health care systems to specialty physician practices. These clients utilize a variety of electronic health record (EHR) systems, as Clairvia’s solutions are EHR-system agnostic and integrate with numerous platforms, including Cerner Millennium®. Clairvia’s Care Value Management suite will be integrated into Cerner’s broader cloud-based and interoperability platforms, Cerner Healthe Intent™ and CareAware®. This will allow Cerner to offer a comprehensive suite of resource management solutions.
“Health care worldwide is experiencing a resourcing deficit that is forecasted to grow dramatically in the next several years,” said Jeff Townsend, Cerner executive vice president and chief of staff. “The fundamental supply of staff and other assets simply cannot meet rising patient demand. Clairvia’s predictive models driven by EHR data not only cut costs by aligning the right resource at the right time but, more importantly, optimize patient outcomes. With this acquisition, we are solidifying our commitment to the workforce management marketplace and interoperable cloud-based solutions that focus on providing positive clinical, operational and financial returns for our clients.”
“EHRs document patient needs and expected courses of care while resource management systems store nurse competency, skills and availability data,” said Pickard, Clairvia president and chief executive officer. “We integrate those two databases in real time, at the point of care. Cerner’s resources and dedication to improving health opens the door for us to create additional solutions that enable health care organizations to accurately forecast demand and to proactively align staffing resources to meet that demand.”
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)